Aptahem AB (publ) (NGM: APTA)
Health Care · Biotechnology · SE
Skr0.50
-12.28% today · -64.3% 1Y
Aptahem AB (publ) (NGM: APTA) operates in the Biotechnology industry within the Health Care sector. The company is valued at $1.37M.
Over the last twelve months the share price has lost 64.3%, trading between 0.32 and 2.40.
Tweenvest scores Aptahem AB (publ) across four factors: quality 47/100, value 63/100. Its strongest factor is value.
APTA price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $1.37M
- Revenue (TTM)
- $264.60K
- P/E
- —
- EPS
- -0.25
- Dividend yield
- —
- Beta (5Y)
- 0.65
- 52-week high
- Skr2.40
- 52-week low
- Skr0.32
- Avg volume (3M)
- —
- Shares outstanding
- 25.93M
- Employees
- —
- Next earnings
- —
Other Biotechnology companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| AbbVie Inc.NYSE: ABBV | $467.44B | $264.52 | -0.17% |
| Amgen Inc.NasdaqGS: AMGN | $239.95B | $443.84 | +1.03% |
| Gilead Sciences, Inc.NasdaqGS: GILD | $181.95B | $146.74 | +0.42% |
| Vertex Pharmaceuticals IncorporatedNasdaqGS: VRTX | $138.79B | $547.59 | -0.08% |
| Regeneron Pharmaceuticals, Inc.NasdaqGS: REGN | $82.73B | $828.50 | -0.66% |
| argenx SEENXTBR: ARGX | $63.06B | €864.20 | -4.19% |
| CSL LimitedASX: CSL | $57.94B | AU$169.11 | +0.48% |
| Moderna, Inc.NasdaqGS: MRNA | $55.45B | $138.89 | -4.26% |
Figures last refreshed Aug 18, 2026.